Meeting
2017 ASCO Annual Meeting
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.
Authors
Takami Sato
Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Takami Sato , Paul D. Nathan , Leonel Fernando Hernandez-Aya , Joseph J Sacco , Marlana M. Orloff , Jessica Truscello , Cheryl McAlpine , Ann-Marie Hulstine , Mark C. Lanasa , Christina Marie Coughlin , Richard D. Carvajal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02570308
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9531)
DOI
10.1200/JCO.2017.35.15_suppl.9531
Abstract #
9531
Poster Bd #
139
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
First Author: Richard D. Carvajal
Poster
2019 ASCO Annual Meeting
Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.
First Author: Mark R. Middleton
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2021 ASCO Annual Meeting
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
First Author: Marlana Orloff